|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ABCC5 |
Gene summary for ABCC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ABCC5 | Gene ID | 10057 |
| Gene name | ATP binding cassette subfamily C member 5 | |
| Gene Alias | ABC33 | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | O15440 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10057 | ABCC5 | CCI_1 | Human | Cervix | CC | 7.46e-14 | 1.44e+00 | 0.528 |
| 10057 | ABCC5 | CCI_2 | Human | Cervix | CC | 2.41e-11 | 1.08e+00 | 0.5249 |
| 10057 | ABCC5 | CCI_3 | Human | Cervix | CC | 1.58e-15 | 9.33e-01 | 0.516 |
| 10057 | ABCC5 | Tumor | Human | Cervix | CC | 2.58e-08 | 3.56e-01 | 0.1241 |
| 10057 | ABCC5 | sample3 | Human | Cervix | CC | 2.34e-12 | 4.61e-01 | 0.1387 |
| 10057 | ABCC5 | T3 | Human | Cervix | CC | 7.10e-18 | 4.65e-01 | 0.1389 |
| 10057 | ABCC5 | LZE2T | Human | Esophagus | ESCC | 2.75e-13 | 2.14e+00 | 0.082 |
| 10057 | ABCC5 | LZE4T | Human | Esophagus | ESCC | 3.46e-25 | 1.22e+00 | 0.0811 |
| 10057 | ABCC5 | LZE7T | Human | Esophagus | ESCC | 1.07e-11 | 1.09e+00 | 0.0667 |
| 10057 | ABCC5 | LZE8T | Human | Esophagus | ESCC | 2.90e-06 | 6.08e-01 | 0.067 |
| 10057 | ABCC5 | LZE20T | Human | Esophagus | ESCC | 2.90e-04 | 2.65e-01 | 0.0662 |
| 10057 | ABCC5 | LZE21D1 | Human | Esophagus | HGIN | 2.64e-07 | 1.69e+00 | 0.0632 |
| 10057 | ABCC5 | LZE22D1 | Human | Esophagus | HGIN | 1.18e-06 | 3.14e-01 | 0.0595 |
| 10057 | ABCC5 | LZE22T | Human | Esophagus | ESCC | 7.49e-05 | 6.54e-01 | 0.068 |
| 10057 | ABCC5 | LZE24T | Human | Esophagus | ESCC | 3.34e-35 | 1.62e+00 | 0.0596 |
| 10057 | ABCC5 | LZE21T | Human | Esophagus | ESCC | 8.88e-24 | 1.84e+00 | 0.0655 |
| 10057 | ABCC5 | P1T-E | Human | Esophagus | ESCC | 6.22e-07 | 5.67e-01 | 0.0875 |
| 10057 | ABCC5 | P2T-E | Human | Esophagus | ESCC | 4.46e-24 | 4.18e-01 | 0.1177 |
| 10057 | ABCC5 | P4T-E | Human | Esophagus | ESCC | 3.94e-50 | 1.40e+00 | 0.1323 |
| 10057 | ABCC5 | P5T-E | Human | Esophagus | ESCC | 1.12e-21 | 3.69e-01 | 0.1327 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
| GO:00158337 | Cervix | CC | peptide transport | 46/2311 | 264/18723 | 9.69e-03 | 4.78e-02 | 46 |
| GO:001593116 | Esophagus | HGIN | nucleobase-containing compound transport | 57/2587 | 222/18723 | 1.76e-06 | 6.52e-05 | 57 |
| GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
| GO:1901264 | Liver | HCC | carbohydrate derivative transport | 48/7958 | 80/18723 | 1.19e-03 | 6.62e-03 | 48 |
| GO:00000411 | Liver | HCC | transition metal ion transport | 59/7958 | 105/18723 | 3.18e-03 | 1.47e-02 | 59 |
| GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
| GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
| GO:0015886 | Liver | HCC | heme transport | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
| GO:00068261 | Liver | HCC | iron ion transport | 34/7958 | 58/18723 | 9.66e-03 | 3.63e-02 | 34 |
| GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
| GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
| GO:00068572 | Oral cavity | OSCC | oligopeptide transport | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
| GO:001593115 | Oral cavity | LP | nucleobase-containing compound transport | 95/4623 | 222/18723 | 2.23e-09 | 9.98e-08 | 95 |
| GO:19012641 | Oral cavity | LP | carbohydrate derivative transport | 31/4623 | 80/18723 | 3.69e-03 | 2.44e-02 | 31 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa015232 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
| hsa0152311 | Esophagus | ESCC | Antifolate resistance | 22/4205 | 30/8465 | 7.23e-03 | 1.76e-02 | 8.99e-03 | 22 |
| hsa01523 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
| hsa020102 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
| hsa015231 | Liver | HCC | Antifolate resistance | 21/4020 | 30/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 21 |
| hsa020103 | Liver | HCC | ABC transporters | 29/4020 | 45/8465 | 1.62e-02 | 3.88e-02 | 2.16e-02 | 29 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ABCC5 | SNV | Missense_Mutation | c.4087N>C | p.Glu1363Gln | p.E1363Q | O15440 | protein_coding | deleterious(0.01) | benign(0.125) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ABCC5 | SNV | Missense_Mutation | rs780239386 | c.2476N>A | p.Glu826Lys | p.E826K | O15440 | protein_coding | tolerated(0.71) | benign(0) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| ABCC5 | SNV | Missense_Mutation | novel | c.1990N>G | p.Arg664Gly | p.R664G | O15440 | protein_coding | tolerated(0.08) | benign(0.07) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| ABCC5 | SNV | Missense_Mutation | rs11552530 | c.3301N>T | p.Arg1101Trp | p.R1101W | O15440 | protein_coding | tolerated(0.12) | possibly_damaging(0.583) | TCGA-D8-A27F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| ABCC5 | SNV | Missense_Mutation | rs747505911 | c.418N>A | p.Glu140Lys | p.E140K | O15440 | protein_coding | deleterious(0) | benign(0.394) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ABCC5 | SNV | Missense_Mutation | c.2856C>G | p.Phe952Leu | p.F952L | O15440 | protein_coding | deleterious(0.01) | possibly_damaging(0.714) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| ABCC5 | SNV | Missense_Mutation | c.2221A>G | p.Thr741Ala | p.T741A | O15440 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ABCC5 | deletion | Frame_Shift_Del | c.3268_3269delNN | p.Leu1090ValfsTer62 | p.L1090Vfs*62 | O15440 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| ABCC5 | SNV | Missense_Mutation | novel | c.2420N>T | p.Ser807Leu | p.S807L | O15440 | protein_coding | tolerated(0.29) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ABCC5 | deletion | Frame_Shift_Del | rs762628168 | c.3269delT | p.Leu1090CysfsTer26 | p.L1090Cfs*26 | O15440 | protein_coding | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | inhibitor | 178101454 | SILDENAFIL | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | irinotecan | IRINOTECAN | 26352872 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | oxaliplatin | OXALIPLATIN | 24924344 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | FLOXURIDINE | FLOXURIDINE | 20930123 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | zidovudine | ZIDOVUDINE | 22960662 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | inhibitor | 252827486 | ||
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | fluorouracil | FLUOROURACIL | 26352872 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | leucovorin | LEUCOVORIN | 26352872 | |
| 10057 | ABCC5 | DRUGGABLE GENOME, ABC TRANSPORTER, TRANSPORTER | glibenclamide | GLYBURIDE | 27403931 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |